NEW YORK, NY / ACCESS Newswire / January 26, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of BioVie Inc. ("BioVie" or "the Company") (NASDAQ:BIVI). Investors who purchased BioVie securities prior to December 7, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/BIVI.
NEW YORK, NY / ACCESSWIRE / January 15, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of BioVie Inc. ("BioVie" or "the Company") (NASDAQ:BIVI). Investors who purchased BioVie securities prior to December 7, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/BIVI.
NEW YORK, NY / ACCESSWIRE / January 5, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of BioVie Inc. ("BioVie" or "the Company") (NASDAQ:BIVI). Investors who purchased BioVie securities prior to December 7, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/BIVI.
NEW YORK, Jan. 02, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against BioVie Inc. (NASDAQ: BIVI) on behalf of long-term stockholders following a class action complaint that was filed against BioVie on January 19, 2024 with a Class Period from August 5, 2021 to November 29, 2023. Our investigation concerns whether the board of directors of BioVie have breached their fiduciary duties to the company.
NEW YORK, NY / ACCESSWIRE / December 29, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of BioVie Inc. ("BioVie" or "the Company") (NASDAQ:BIVI). Investors who purchased BioVie securities prior to December 7, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/BIVI.
NEW YORK, NY / ACCESSWIRE / December 24, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of BioVie Inc. ("BioVie" or "the Company") (NASDAQ:BIVI). Investors who purchased BioVie securities prior to December 7, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/BIVI.
NEW YORK, NY / ACCESSWIRE / December 22, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of BioVie Inc. ("BioVie" or "the Company") (NASDAQ:BIVI). Investors who purchased BioVie securities prior to December 7, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/BIVI.
NEW YORK, NY / ACCESSWIRE / December 18, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of BioVie Inc. ("BioVie" or "the Company") (NASDAQ:BIVI). Investors who purchased BioVie securities prior to December 7, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/BIVI.
NEW YORK, NY / ACCESSWIRE / December 15, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of BioVie Inc. ("BioVie" or "the Company") (NASDAQ:BIVI). Investors who purchased BioVie securities prior to December 7, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/BIVI.
NEW YORK, NY / ACCESSWIRE / December 11, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of BioVie Inc. ("BioVie" or "the Company") (NASDAQ:BIVI). Investors who purchased BioVie securities prior to December 7, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/BIVI.